-
APLT Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Applied Therapeutics (APLT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.87 mm | 98.87 mm | 98.87 mm | 98.87 mm | 98.87 mm | 98.87 mm |
Cash burn (monthly) | 7.78 mm | (no burn) | 9.91 mm | 7.69 mm | 7.78 mm | 6.82 mm |
Cash used (since last report) | 33.12 mm | n/a | 42.23 mm | 32.75 mm | 33.12 mm | 29.05 mm |
Cash remaining | 65.75 mm | n/a | 56.64 mm | 66.11 mm | 65.75 mm | 69.82 mm |
Runway (months of cash) | 8.5 | n/a | 5.7 | 8.6 | 8.5 | 10.2 |
13F holders | Current |
---|---|
Total holders | 135 |
Opened positions | 52 |
Closed positions | 17 |
Increased positions | 33 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 948.45 bn |
Total shares | 138.43 mm |
Total puts | 1.91 mm |
Total calls | 1.68 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
ARE Alexandria Real Estate Equities | 12.56 mm | $113.41 mm |
Venrock Healthcare Capital Partners III | 11.66 mm | $105.25 mm |
JHG Janus Henderson | 10.54 mm | $89.66 bn |
MS Morgan Stanley | 9.90 mm | $84.19 bn |
VR Adviser | 9.82 mm | $83.51 bn |
Perceptive Advisors | 8.01 mm | $68.04 bn |
BlackRock | 6.94 mm | $59.01 bn |
BEN Franklin Resources | 6.80 mm | $60.46 bn |
Propel Bio Management | 6.57 mm | $55.83 bn |
Knoll Capital Management | 5.57 mm | $47.38 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Dec 24 | Johnson John | Common Stock | Grant | Acquire A | No | No | 0 | 500,000 | 0.00 | 500,000 |
19 Dec 24 | Johnson John | Stock Option Common Stock | Grant | Acquire A | No | No | 1.02 | 1,000,000 | 1.02 mm | 1,000,000 |
19 Dec 24 | Funtleyder Leslie D. | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 427,911 |
19 Dec 24 | Funtleyder Leslie D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.02 | 150,000 | 153.00 k | 150,000 |
22 Aug 24 | Riccardo Perfetti | Common Stock | Sell | Dispose S | No | No | 5.83 | 22,681 | 132.23 k | 986,853 |
22 Aug 24 | Funtleyder Leslie D. | Common Stock | Sell | Dispose S | No | No | 5.83 | 13,530 | 78.88 k | 277,911 |